The terms of these agreements are confidential. ABBV will receive royalties from the Humira-biosimilar companies who settle the patent litigation because part of the settlement agreements is an admission that ABBV's US formulation and method-of-use patents on Humira are valid.
News 
Market Data 
Discover 
